C4X Discovery Holdings PLC | Mutual Funds
Mutual Funds that own C4X Discovery Holdings PLC
City Financial Absolute Equity Fund
2,145,000
4.61%
0
0.84%
09/29/2017
Marlborough UK Micro Cap Growth Fund
2,110,704
4.53%
28,569
0.16%
03/29/2018
Herald Investment Trust Plc
1,481,016
3.18%
1,481,016
0.13%
12/31/2017
Polar Capital Funds Plc - Biotechnology Fund
1,250,000
2.69%
0
0.31%
07/31/2018
Edinburgh Worldwide Investment Trust Plc
1,104,989
2.37%
0
0.22%
10/31/2017
Baillie Gifford Overseas Growth Fund - Global Discovery Fund
916,104
1.97%
0
0.17%
04/30/2018
373,828
0.8%
5,060
0.2%
03/29/2018
Investec Structured Products Calculus VCT Plc
0
0%
-70,827
0%
02/28/2018
| Address |
Manchester One
Manchester Greater Manchester M1 3LD
United Kingdom
|
|
Employees
|
- |
| Website |
http://c4xdiscovery.com/ |
| Updated |
07/08/2019 |
| C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. Its software platforms consists of Taxonomy3, which utilizes a mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases; and Conformetrix, which determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. |
